tetano
Editor, Senior Moderator
J Hematol Oncol
. 2023 Apr 1;16(1):32.
doi: 10.1186/s13045-023-01423-7.
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
Francesco Marchesi[SUP] #[/SUP][SUP] 1 [/SUP], Jon Salmanton-García[SUP] #[/SUP][SUP] 2 3 4 [/SUP], Caterina Buquicchio[SUP] #[/SUP][SUP] 5 [/SUP], Federico Itri[SUP] 6 [/SUP], Caroline Besson[SUP] 7 8 [/SUP], Julio Dávila-Valls[SUP] 9 [/SUP], Sonia Martín-Pérez[SUP] 9 [/SUP], Luana Fianchi[SUP] 10 [/SUP], Laman Rahimli[SUP] 11 12 [/SUP], Giuseppe Tarantini[SUP] 5 [/SUP], Federica Irene Grifoni[SUP] 13 [/SUP], Mariarita Sciume[SUP] 14 [/SUP], Jorge Labrador[SUP] 15 16 [/SUP], Raul Cordoba[SUP] 17 [/SUP], Alberto López-García[SUP] 17 [/SUP], Nicola S Fracchiolla[SUP] 14 [/SUP], Francesca Farina[SUP] 18 [/SUP], Emanuele Ammatuna[SUP] 19 [/SUP], Antonella Cingolani[SUP] 20 [/SUP], Daniel García-Bordallo[SUP] 21 [/SUP], Stefanie K Gräfe[SUP] 11 10 22 [/SUP], Yavuz M Bilgin[SUP] 23 [/SUP], Michelina Dargenio[SUP] 24 [/SUP], Tomás José González-López[SUP] 25 [/SUP], Anna Guidetti[SUP] 26 [/SUP], Tobias Lahmer[SUP] 27 [/SUP], Esperanza Lavilla-Rubira[SUP] 21 [/SUP], Gustavo-Adolfo Méndez[SUP] 28 [/SUP], Lucia Prezioso[SUP] 29 [/SUP], Martin Schönlein[SUP] 30 [/SUP], Jaap Van Doesum[SUP] 19 [/SUP], Dominik Wolf[SUP] 31 [/SUP], Ditte Stampe Hersby[SUP] 32 [/SUP], Ferenc Magyari[SUP] 33 [/SUP], Jens Van Praet[SUP] 34 [/SUP], Verena Petzer[SUP] 31 [/SUP], Carlo Tascini[SUP] 35 [/SUP], Iker Falces-Romero[SUP] 36 37 [/SUP], Andreas Glenthøj[SUP] 32 [/SUP], Oliver A Cornely[SUP] 11 38 12 39 40 [/SUP], Livio Pagano[SUP] 10 41 [/SUP]
Affiliations
Abstract
Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.
Keywords: COVID-19; Hematologic malignancies; Passive immunization; Tixagevimab/cilgavimab.
. 2023 Apr 1;16(1):32.
doi: 10.1186/s13045-023-01423-7.
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
Francesco Marchesi[SUP] #[/SUP][SUP] 1 [/SUP], Jon Salmanton-García[SUP] #[/SUP][SUP] 2 3 4 [/SUP], Caterina Buquicchio[SUP] #[/SUP][SUP] 5 [/SUP], Federico Itri[SUP] 6 [/SUP], Caroline Besson[SUP] 7 8 [/SUP], Julio Dávila-Valls[SUP] 9 [/SUP], Sonia Martín-Pérez[SUP] 9 [/SUP], Luana Fianchi[SUP] 10 [/SUP], Laman Rahimli[SUP] 11 12 [/SUP], Giuseppe Tarantini[SUP] 5 [/SUP], Federica Irene Grifoni[SUP] 13 [/SUP], Mariarita Sciume[SUP] 14 [/SUP], Jorge Labrador[SUP] 15 16 [/SUP], Raul Cordoba[SUP] 17 [/SUP], Alberto López-García[SUP] 17 [/SUP], Nicola S Fracchiolla[SUP] 14 [/SUP], Francesca Farina[SUP] 18 [/SUP], Emanuele Ammatuna[SUP] 19 [/SUP], Antonella Cingolani[SUP] 20 [/SUP], Daniel García-Bordallo[SUP] 21 [/SUP], Stefanie K Gräfe[SUP] 11 10 22 [/SUP], Yavuz M Bilgin[SUP] 23 [/SUP], Michelina Dargenio[SUP] 24 [/SUP], Tomás José González-López[SUP] 25 [/SUP], Anna Guidetti[SUP] 26 [/SUP], Tobias Lahmer[SUP] 27 [/SUP], Esperanza Lavilla-Rubira[SUP] 21 [/SUP], Gustavo-Adolfo Méndez[SUP] 28 [/SUP], Lucia Prezioso[SUP] 29 [/SUP], Martin Schönlein[SUP] 30 [/SUP], Jaap Van Doesum[SUP] 19 [/SUP], Dominik Wolf[SUP] 31 [/SUP], Ditte Stampe Hersby[SUP] 32 [/SUP], Ferenc Magyari[SUP] 33 [/SUP], Jens Van Praet[SUP] 34 [/SUP], Verena Petzer[SUP] 31 [/SUP], Carlo Tascini[SUP] 35 [/SUP], Iker Falces-Romero[SUP] 36 37 [/SUP], Andreas Glenthøj[SUP] 32 [/SUP], Oliver A Cornely[SUP] 11 38 12 39 40 [/SUP], Livio Pagano[SUP] 10 41 [/SUP]
Affiliations
- PMID: 37005697
- DOI: 10.1186/s13045-023-01423-7
Abstract
Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.
Keywords: COVID-19; Hematologic malignancies; Passive immunization; Tixagevimab/cilgavimab.